The DYRK1A Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This product features targeted disruption of the DYRK1A gene, eliminating the expression of functional dual-specificity tyrosine-phosphorylation-regulated kinase 1A. The polyclonal nature ensures a mixture of edited cells, providing a robust population for functional studies without monoclonal selection. The knockout abrogates DYRK1A kinase activity, enabling loss-of-function analyses in a consistent cellular background.
The A-549 cell line is a widely used model of alveolar type II pneumocytes, isolated from a human lung carcinoma. These adherent epithelial cells exhibit characteristics of lung adenocarcinoma, making them highly relevant for cancer biology, drug metabolism, and pulmonary disease research. The cells are competent for studying signal transduction pathways implicated in tumorigenesis, including NFAT, Wnt, and Hedgehog cascades. The A-549 background provides a physiologically meaningful context for investigating DYRK1A??s role in lung cancer, as the kinase is known to modulate proliferation and survival in such cells.
DYRK1A is a proline-directed serine/threonine kinase that phosphorylates a broad array of substrates involved in cell cycle progression, differentiation, and neuronal development. In the A-549 context, DYRK1A is activated upstream by MAPK/ERK signaling and forms complexes with regulatory proteins such as DCAF7/WDR68, RCAN1, and 14-3-3 adaptors. The kinase directly phosphorylates key transducers including NFATc1, tau, and presenilin 1, thereby influencing their localization and activity. DYRK1A also phosphorylates cyclin D1 and c-Myc, linking its activity to proliferative control. Through these interactions, DYRK1A integrates inputs from the Hedgehog and Wnt/??-catenin pathways to modulate transcriptional programs. Knockout of DYRK1A disrupts these phosphorylation events, leading to altered nuclear-cytoplasmic shuttling of NFAT and changes in downstream gene expression, ultimately impinging on cell cycle and apoptotic networks.
Elimination of DYRK1A kinase activity in A-549 cells provides a valuable loss-of-function model for dissecting signaling mechanisms specific to lung adenocarcinoma. The knockout impairs phosphorylation of NFATc, preventing its nuclear export and thereby sustaining NFAT transcriptional activity, while concurrently reducing DYRK1A-mediated phosphorylation of tau and other substrates. This disruption alters cell proliferation dynamics and may attenuate the tumorigenic potential of A-549 cells, as DYRK1A overexpression has been associated with poor prognosis in certain cancers. The model thus enables researchers to assess the dependency of lung cancer pathways on DYRK1A catalytic function, offering insights into its role as a potential oncogenic driver.
These polyclonal knockout cells are suited for functional dissection of NFAT and Wnt signaling, drug target validation, and phenotypic screening of small-molecule DYRK1A inhibitors. Representative assays include Western blotting, RT-qPCR, cell proliferation and migration assays, and phospho-NFAT ELISA. The cells also support drug sensitivity screening. Overall, these cells provide a versatile platform for academic and pharmaceutical studies. For additional details, please contact Ascent Research.
